AU2022409839B2 - Ophthalmic pharmaceutical compositions and uses thereof - Google Patents

Ophthalmic pharmaceutical compositions and uses thereof

Info

Publication number
AU2022409839B2
AU2022409839B2 AU2022409839A AU2022409839A AU2022409839B2 AU 2022409839 B2 AU2022409839 B2 AU 2022409839B2 AU 2022409839 A AU2022409839 A AU 2022409839A AU 2022409839 A AU2022409839 A AU 2022409839A AU 2022409839 B2 AU2022409839 B2 AU 2022409839B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
ophthalmic pharmaceutical
subject
ophthalmic
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022409839A
Other languages
English (en)
Other versions
AU2022409839A1 (en
Inventor
Anjali Joshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AU2022409839A1 publication Critical patent/AU2022409839A1/en
Assigned to ALCON INC. reassignment ALCON INC. Request for Assignment Assignors: AERIE PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2022409839B2 publication Critical patent/AU2022409839B2/en
Priority to AU2026201834A priority Critical patent/AU2026201834A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022409839A 2021-12-17 2022-12-16 Ophthalmic pharmaceutical compositions and uses thereof Active AU2022409839B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026201834A AU2026201834A1 (en) 2021-12-17 2026-03-11 Ophthalmic pharmaceutical compositions and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163290781P 2021-12-17 2021-12-17
US63/290,781 2021-12-17
PCT/US2022/081775 WO2023114986A1 (en) 2021-12-17 2022-12-16 Ophthalmic pharmaceutical compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026201834A Division AU2026201834A1 (en) 2021-12-17 2026-03-11 Ophthalmic pharmaceutical compositions and uses thereof

Publications (2)

Publication Number Publication Date
AU2022409839A1 AU2022409839A1 (en) 2024-07-11
AU2022409839B2 true AU2022409839B2 (en) 2025-12-11

Family

ID=85157426

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022409839A Active AU2022409839B2 (en) 2021-12-17 2022-12-16 Ophthalmic pharmaceutical compositions and uses thereof
AU2026201834A Pending AU2026201834A1 (en) 2021-12-17 2026-03-11 Ophthalmic pharmaceutical compositions and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026201834A Pending AU2026201834A1 (en) 2021-12-17 2026-03-11 Ophthalmic pharmaceutical compositions and uses thereof

Country Status (10)

Country Link
US (3) US11850221B2 (enExample)
EP (1) EP4447935A1 (enExample)
JP (1) JP2024544393A (enExample)
KR (1) KR20240121320A (enExample)
CN (1) CN118076340A (enExample)
AU (2) AU2022409839B2 (enExample)
CA (1) CA3242833A1 (enExample)
IL (1) IL313616A (enExample)
MX (1) MX2024007092A (enExample)
WO (1) WO2023114986A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3242833A1 (en) 2021-12-17 2023-06-22 Alcon Inc. OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND THEIR USES
US20250384550A1 (en) * 2023-06-09 2025-12-18 Chung Shan Medical University Reagent and kit for identifying and diagnosis ocular surface disease (osd) and use thereof
US20260027050A1 (en) * 2024-07-23 2026-01-29 Alcon Inc. Acoltremon combinations and uses thereof
WO2026154426A1 (en) * 2025-01-16 2026-07-23 Alcon Inc. Ophthalmic pharmaceutical compositions and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3705114A1 (en) * 2019-03-06 2020-09-09 Avizorex Pharma, S.L. Ophthalmic composition for treating dry eye and symptoms thereof
WO2021195256A1 (en) * 2020-03-24 2021-09-30 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1067684A (ja) 1996-06-17 1998-03-10 Mitsubishi Chem Corp 涙液分泌促進剤
JPH10236972A (ja) 1997-02-28 1998-09-08 Mitsubishi Chem Corp 涙液分泌促進剤
JP3142842B1 (ja) 1999-10-22 2001-03-07 ライオン株式会社 眼科用組成物及びソフトコンタクトレンズへの吸着抑制方法
US6569903B2 (en) 1999-12-07 2003-05-27 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
US20020009507A1 (en) 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
AU2003210663A1 (en) 2002-01-25 2003-09-02 The Regents Of The University Of California Methods of modulating cold sensory perception
US20060084684A1 (en) 2002-05-28 2006-04-20 Altana Pharma Ag Topically applicable pharmaceutical preparation
US6919348B2 (en) 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
DE10259619A1 (de) 2002-12-18 2004-07-08 Metagen Pharmaceuticals Gmbh Verwendung einer TRPM8 aktivierenden Substanz zur Tumorbehandlung
CA2530884C (en) 2003-07-02 2016-01-12 Genentech, Inc. Trp-p8 active compounds and therapeutic treatment methods
US20050137166A1 (en) 2003-12-19 2005-06-23 Alcon, Inc. Use of cooling agents to relieve mild ocular irritation and enhance comfort
EP1802600A1 (en) 2004-10-13 2007-07-04 Bayer HealthCare AG Substituted 4-benzyloxy-phenylmethylamide derivatives as cold menthol receptor-1 (cmr-1) antagonits for the treatment of urological disorders
US20060111388A1 (en) 2004-11-19 2006-05-25 University Of North Texas Health Science Center At Fort Worth Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
JP5078254B2 (ja) 2004-12-17 2012-11-21 ロート製薬株式会社 眼科用組成物
GB0504194D0 (en) 2005-03-02 2005-04-06 Givaudan Sa Organic compounds
WO2007017092A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 4-benzyloxy-benzoic acid amide derivatives
US7727516B2 (en) 2006-02-28 2010-06-01 The Procter & Gamble Company Reduction of hair growth
CN101405009B (zh) 2006-03-23 2011-04-13 千寿制药株式会社 包含黄原胶和葡萄糖的眼科组合物
US7887859B2 (en) 2006-11-02 2011-02-15 Riolan Technologies, Inc. Methods of treating epiphora
GB2451503B (en) 2007-08-01 2011-10-12 Lrc Products Stimulating gel comprising a cyclic carboxamide coolant
FR2934778B1 (fr) 2008-08-11 2012-09-28 Natura Cosmeticos Sa Compositions d'anti-transpirants et procedes permettant de reduire la transpiration chez les humains
US8653099B2 (en) 2008-08-19 2014-02-18 Janssen Pharmaceutica Cold menthol receptor antagonists
ES2377785B2 (es) * 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
KR102073258B1 (ko) 2014-04-15 2020-02-04 비쭈리 헬스 사이언스 엘엘씨 통증 완화용 국소 조성물, 제조방법 및 용도
ES2625393A1 (es) 2016-01-19 2017-07-19 Universidad Miguel Hernandez De Elche Compuestos agonistas del receptor trpm8 y sus aplicaciones
US20180252700A1 (en) 2016-10-06 2018-09-06 Ora, Inc. Screening agents in dry eye disease
US20220080048A1 (en) * 2016-10-12 2022-03-17 PS Therapy Ltd Opthalmological compositions and methods of use thereof
CN110996904A (zh) 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
CA3242833A1 (en) 2021-12-17 2023-06-22 Alcon Inc. OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND THEIR USES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3705114A1 (en) * 2019-03-06 2020-09-09 Avizorex Pharma, S.L. Ophthalmic composition for treating dry eye and symptoms thereof
WO2021195256A1 (en) * 2020-03-24 2021-09-30 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation

Also Published As

Publication number Publication date
JP2024544393A (ja) 2024-11-29
EP4447935A1 (en) 2024-10-23
IL313616A (en) 2024-08-01
US12336971B2 (en) 2025-06-24
MX2024007092A (es) 2024-06-26
CN118076340A (zh) 2024-05-24
US20230233493A1 (en) 2023-07-27
WO2023114986A1 (en) 2023-06-22
AU2026201834A1 (en) 2026-04-02
CA3242833A1 (en) 2023-06-22
US20250281434A1 (en) 2025-09-11
US20240091179A1 (en) 2024-03-21
KR20240121320A (ko) 2024-08-08
AU2022409839A1 (en) 2024-07-11
US11850221B2 (en) 2023-12-26

Similar Documents

Publication Publication Date Title
US12336971B2 (en) Ophthalmic pharmaceutical compositions and uses thereof
US8765787B2 (en) Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen
US9012503B2 (en) Ophthalmic composition
US11285163B2 (en) Ophthalmic solution
US20200306218A1 (en) Ophthalmic composition for treating dry eye and symptoms thereof
WO2013052760A1 (en) Compositions for the treatment of dry eye
CN111888326B (zh) 羟甲唑啉组合物和用于治疗眼障碍的方法
IT201800007677A1 (it) Liposomi per il trattamento di patologie oculari
GR1009006B (el) Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χρηση περιεχον βιματοπροστη και τιμολολη
US20230233687A1 (en) Hyaluronic acid-based formulations for treatment and prevention of ocular hypertension and glaucoma
JP2023038930A (ja) 眼表面薬物滞留化剤およびこれを含む点眼剤、並びに、これらの剤を用いた眼表面薬物滞留方法および眼科疾患治療方法
KR102268002B1 (ko) 효과 지속성 점안제 조성물
JP2001302545A (ja) 清涼化剤
CN103202833A (zh) 一种奥洛他定或其盐的药用组合物及其制备方法
KR20220089106A (ko) 도르졸라마이드 또는 폴리소르베이트80을 유효성분으로 포함하는 점안용 조성물
RU2820596C2 (ru) Композиции оксиметазолина и способы для лечения офтальмологических расстройств
JP7417531B2 (ja) 選択的ｓｙｋ阻害剤の使用方法および医薬組成物
HK40100508A (en) Oxymetazoline compositions and methods for treating ocular disorders
US20250114375A1 (en) Pharmaceutical composition of lifitegrast and loteprednol etabonate
JP2024090835A (ja) 組織移行性を向上させるエピナスチン含有水性組成物
HK40031931B (en) Oxymetazoline compositions and methods for treating ocular disorders

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ALCON INC.

Free format text: FORMER APPLICANT(S): AERIE PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)